A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC-9)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503999-24-00

Acronym

D9078C00001

Enrollment

437

Registered

2024-02-13

Start date

2022-06-01

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC)

Brief summary

Progression Free Survival (PFS) as assessed by BICR, per RECIST 1.1. Up to 5 years after first patient randomized.

Interventions

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGMYCOPHENOLATE MOFETIL

DRUGGLUCOSE

DRUGSODIUM CHLORIDE

DRUGINFLIXIMAB

DRUGOleclumab

DRUGMonalizumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression Free Survival (PFS) as assessed by BICR, per RECIST 1.1. Up to 5 years after first patient randomized.	—

Countries

France, Germany, Italy, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026